← All trials
NCT05612984
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Jan 31, 2026
- Completion date
- Apr 30, 2026
- First posted
- Nov 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 12000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- Aga Khan UniversityCollaborator
- Columbia UniversityCollaborator
- Zvitambo Institute for Maternal and Child Health ResearchCollaborator
- Johns Hopkins UniversityOfficial
- Thomas Jefferson UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.